- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Mavenclad, Leustatin
Synonyms :
Class :
Anticancer and antimetabolites
Dosage forms & Strengths
Solution, Intravenous
10 mg/10 ml
Tablet, Oral
10 mg
Note: Do not start or continue therapy until lymphocytes > 800 cell/mm3
5
mg/m^2
Intravenous (IV)
5
days
daily infused over 3 hours, generally given in combination with daunorubicin and cytarabine
CLAG regimen:
5
mg/m^2
Intravenous (IV)
Over 2 hr
5
days
given in combination with cytarabine, filgrastim and mitoxantrone
0.09 - 0.1
mg/kg
Intravenous (IV)
continuous infusion
7
days
or 0.15 mg/kg/day IV over 2 hr for 5 days in combination with rituximab
5
mg/m^2
Intravenous (IV)
Over 2 hr
5
days
every 4 weeks as cycle 1, continue till 2 to 6 cycles
1.75
mg/kg
Oral
per year for a total dose of 3.5 mg/kg over 2 years (NMT 20mg/day)
0.1
mg/kg
Intravenous (IV)
once a day
7
days
every 4 weeks or 0.1 mg/kg SUBQ per day for 5 days every month in combination with rituximab
Dose Adjustments
CrCl 10 to 50 ml/minute: administer 75% of dose
CrCl <10 ml/minute: administer 50% of dose
CAPD: administer 50% of dose
CrCl > 60 ml/minute: no dosage adjustment necessary
CrCl < 60 ml/minute: use is not recommended
Hemodialysis: use is not recommended
eGFR <50 ml/minute: use not recommended
For moderate to severe hepatic impairment: use is not recommended
Dosage forms & Strengths
Solution, Intravenous
10 mg/10 ml
Tablet, Oral
10 mg
Note: Do not start or continue therapy until lymphocytes > 800 cell/mm3
Children and adolescents:
8.9
mg/m^2
Intravenous (IV)
once a day
5
days
Children and adolescents:
5
mg/m^2
Intravenous (IV)
once a day
over 2 hrs for 5 days for a 21-day cycle
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
may enhance the serum concentration
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 Inhibitors
may increase excessive immunosuppressive effects and risk of infection
adenovirus types and live oral
may reduce therapeutic effects of the vaccine
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
clozapine
increase immunosuppressive effects and risk of infection
may raise the risk of pancytopenia and agranulocytosis due to myelosuppression
may increase bone marrow suppression
increases the serum concentration of BCRP/ABCG2 substrates
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
increase toxic adverse effects of cladribine
may increase bone marrow suppression
may increase bone marrow suppression
increase immunosuppressive effects and risk of infection
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the myelosuppressive effect of myelosuppressive agents
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both the drugs are combined, the risk or severity of adverse effects increases
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of serious infections
high-risk for serious infections due to increasing immunosuppression
high-risk for serious infections due to increasing immunosuppression
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
may increase myelosuppression and immunosuppression
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine
when both drugs are combined, there may be an increase in the risk of the myelosuppressive effect of myelosuppressive agents
it may increase the bone marrow suppression effect of cladribine
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in the myelosuppressive effect
it enhances the myelosuppressive activity of cladribine
the effect of myelosuppression is increased in myelosuppressive agents
it increases the effect of myelosuppression in myelosuppressive agents
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
may increase the immunosuppressive effects
may increase the immunosuppressive effect
may increase the immunosuppressive effects
may increase the toxic effect
may increase the toxic effect
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of immunosuppressants
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the immunosuppressive effect of Immunosuppressive agents
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the immunosuppressive effect of Immunosuppressants
may increase the myelosuppressive effect of Myelosuppressive Agents
increase immunosuppressive effects and risk of infection
may diminish immune response to cholera vaccine
may diminish immune response to dengue vaccine
increased risk of serious infection due to impaired immune system
may manifest acute “recall” pneumonitis after radiation therapy
